Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...

lCritical Illness, Brain Dysfunction, and Survivorship Center (CIBS), Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University Medical Center, ...

hRoyal Marsden Hospital, NHS Foundation Trust, London and Surrey, UK iSheffield Teaching Hospital, NHS Foundation Trust, Sheffield and London, UK ...

Shifting attention away from a visual stimulus reduces, but does not abolish, visual discrimination performance. This residual vision with 'poor' attention can be compared to normal vision with 'full' ...

Summary: A global meta-analysis of over 4,700 survivors has revealed that psychiatric and behavioral complications, such as depression, anxiety, and emotional instability, are widespread following ...